arsenic trioxide has been researched along with px 478 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, J; Hao, J; Huang, C; Lan, C; Lang, M; Li, X; Ren, H; Wang, H; Wang, X; Yang, S; Yang, Y; Yu, M | 1 |
1 other study(ies) available for arsenic trioxide and px 478
| Article | Year |
|---|---|
Arsenic trioxide plus PX-478 achieves effective treatment in pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; Arsenicals; Binding Sites; Carcinoma, Pancreatic Ductal; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice, Nude; Mustard Compounds; Oxidative Stress; Oxides; Pancreatic Neoplasms; Phenylpropionates; Promoter Regions, Genetic; Reactive Oxygen Species; RNA Interference; Signal Transduction; Time Factors; Transcriptional Activation; Transfection; Xenograft Model Antitumor Assays | 2016 |